You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Vandetanib, NSCLC, Maintenance, Phase II

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Urothelial Carcinoma Trial in Québec (Bicalutamide 150 mg, Placebo)

Not yet recruiting
  • Metastatic Urothelial Carcinoma
  • Bicalutamide 150 mg
  • Placebo
  • Québec, Canada
    CHU de Québec - Université Laval
Sep 6, 2023

NSCLC Metastatic Trial in Seoul (Lazertinib, Tepotinib)

Not yet recruiting
  • Non-Small Cell Lung Cancer Metastatic
  • Seoul, Gangnam-gu, Korea, Republic of
    Samsung Medical Center
Oct 27, 2023

Metastatic Squamous Non-Small Cell Lung Carcinoma Trial in Chicago (Cabozantinib 40 MG, Pembrolizumab 200mg)

Recruiting
  • Metastatic Squamous Non-Small Cell Lung Carcinoma
  • Cabozantinib 40 MG
  • Pembrolizumab 200mg
  • Chicago, Illinois
    University of Illinois at Chicago
Jan 20, 2023

NSCLC Trial in Zhengzhou (Tislelizumab)

Active, not recruiting
  • NSCLC
  • Zhengzhou, Hennan, China
    The First Affiliated Hospital of Zhengzhou University
Oct 31, 2022

ALK Positive NSCLC Trial in Guangzhou (Loratinib)

Recruiting
  • ALK Positive Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial Perople's Hospital
Oct 19, 2023

NSCLC Trial in Philadelphia (Carboplatin, Paclitaxel, Ramucirumab)

Recruiting
  • Non-small Cell Lung Cancer
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Mar 14, 2022

Colorectal Cancer Metastatic Trial in Guangzhou (Fruquintinib)

Recruiting
  • Colorectal Cancer Metastatic
  • Guangzhou, Guangdong, China
    Colorectal Department,SunYat-sen University Cancer Center
Aug 28, 2023

Ovarian Cancer, Drug Related Tumor/Cancer Trial (secondary cytoreductive surgery, chemo)

Not yet recruiting
  • Ovarian Cancer
  • Drug Related Neoplasm/Cancer
  • (no location specified)
Jan 28, 2023

Prostatic Adenocarcinoma Trial in Seoul (Enzalutamide)

Not yet recruiting
  • Prostatic Adenocarcinoma
  • Seoul, Korea, Korea, Republic of
    Samsung Medical Center
Aug 23, 2023

Non-small-cell Lung Carcinoma Trial in Beijing (SY-3505)

Recruiting
  • Non-small-cell Lung Carcinoma
  • Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
May 11, 2023

Unresectable Lung Non-Small Cell Carcinoma Trial (serplulimab plus chemo as conversion treatment)

Not yet recruiting
  • Unresectable Lung Non-Small Cell Carcinoma
  • serplulimab plus chemotherapy as conversion treatment
  • (no location specified)
Apr 27, 2023

NSCLC Trial in Davis, San Francisco (Ceritinib, Trametinib)

Terminated
  • Non-small Cell Lung Cancer
  • Davis, California
  • +1 more
Dec 22, 2022

NSCLC Trial (AK119, AK112, Pemetrexed)

Not yet recruiting
  • NSCLC
  • (no location specified)
Nov 23, 2022

NSCLC Stage IV Trial in Gauting (combination regimen tremelimumab /durvalumab, platinum-based chemo (SoC))

Withdrawn
  • NSCLC Stage IV
  • combination regimen tremelimumab /durvalumab
  • platinum-based chemotherapy (SoC)
  • Gauting, Germany
    Asklepios Fachkliniken München-Gauting
Sep 26, 2022

NSCLC Trial in Shanghai (Toripalimab, Cryoablation)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Nov 7, 2023

NSCLC (NSCLC) Trial in New York (Pembrolizumab)

Not yet recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • New York, New York
    Mount Sinai Hospital
Jan 23, 2023

Non-small Cell Lung Carcinoma Trial (BPI-361175)

Not yet recruiting
  • Non-small Cell Lung Carcinoma
  • (no location specified)
Oct 18, 2022

Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Trial in Beijing (Niraparib)

Recruiting
  • Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Nov 15, 2023

Non-small-cell Lung Cancer Trial (HL-085+Vemurafenib)

Not yet recruiting
  • Non-small-cell Lung Cancer
  • (no location specified)
Jun 8, 2023

Aspirin in Combination With Trametinib and Dabrafenib

Not yet recruiting
  • NSCLC
  • +4 more
  • Combind asprin with Trametinib and Dabrafenib
  • (no location specified)
Aug 4, 2023

NSCLC Trial in Shanghai (SH-1028 tablets, Placebo SH-1028 tablets)

Recruiting
  • Non-small Cell Lung Cancer
  • SH-1028 tablets
  • Placebo SH-1028 tablets
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Oct 6, 2023

Cancer of Pancreas Trial in Cairo (Capecitabine, follow up)

Recruiting
  • Cancer of Pancreas
  • Cairo, Egypt
  • +2 more
Sep 30, 2022

NSCLC Trial in Houston (Amivantamab, Tepotinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Houston, Texas
    MD Anderson Cancer Center
Oct 9, 2023

NSCLC Stage III, Radiotherapy Side Effect, Frailty Trial (Photon, Proton)

Not yet recruiting
  • Non-small Cell Lung Cancer Stage III
  • +2 more
  • Photon
  • Proton
  • (no location specified)
Sep 20, 2022

NSCLC Trial in Changsha (AK104+anlotinib)

Active, not recruiting
  • NSCLC
  • Changsha, Hunan, China
    Hunan cancer hospital
May 18, 2022